Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. The company is headquartered in Redwood City, California and currently employs 700 full-time employees. The company went IPO on 2020-02-13. The Company’s research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. The company’s RAS(ON) inhibitors are daraxonrasib (RMC-6236), an RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), an RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are in clinical development. The Company’s pipeline also focuses on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C).
Follow-Up Questions
Who is the CEO of Revolution Medicines Inc?
Dr. Mark Goldsmith is the Chairman of the Board of Revolution Medicines Inc, joining the firm since 2014.
What is the price performance of RVMD stock?
The current price of RVMD is $58.72, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Revolution Medicines Inc?
Revolution Medicines Inc belongs to Biotechnology industry and the sector is Health Care
What is Revolution Medicines Inc market cap?
Revolution Medicines Inc's current market cap is $10.9B
Is Revolution Medicines Inc a buy, sell, or hold?
According to wall street analysts, 21 analysts have made analyst ratings for Revolution Medicines Inc, including 8 strong buy, 13 buy, 1 hold, 0 sell, and 8 strong sell
